FDA says new patients should not use Avandia

In this June 30, 2010 file photo, a pharmacist holds a bottle of Avandia pills at Maximart Pharmacy in Palo Alto, Calif. Federal health advisers discuss whether GlaxoSmithKline's diabetes pill Avandia should be pulled from the market. The one-time-blockbuster drug's sales have shrunk markedly since studies suggested potential ties to heart attacks. (AP Photo/Paul Sakuma, file)

July 21, 2010 10:26:53 AM PDT
Federal health officials say new patients should not be enrolled in a study of the controversial diabetes pill Avandia.

Experts advising the government voted last week that the drug appears to increase heart risks. They also recommend leaving the Glaxo-Smith-Kline drug on the market for now because the evidence is not definitive.

The Food and Drug Administration is now deciding what action to take. In the meantime, it has put on hold a study of whether Avandia is less safe than its competitor Actos.